

Changes to QIPP Prescribing Comparators (April 2013)

Paul Brown 15th April 2013

Introduction

This document details the changes that are to be made to the QIPP prescribing comparators developed to support the 'Key Therapeutic Topics - Medicines management options for local implementation' publication (MPC, NICE). The changes will be implemented from quarter 1 2013/14 data (available August 2013) onwards.

The changes take into account feedback received from NHS and commercial partners. A separate document, 'QIPP prescribing comparators feedback April 2013', details the feedback received and responses to the feedback and is available on the Health & Social Care Information Centre website (Update - April 2013)

Full details of all the current comparators are detailed in 'QIPP Prescribing Comparators Descriptions and Specifications (August 2012)', also available on the Health & Social Care Information website. NB: The document will be updated shortly to incorporate changes to the comparators.

Summary of changes

The current QIPP prescribing comparators are to remain unchanged for 2013/14 with the exception of the following:

1. Low cost lipid modifying drugs

The current comparator is to be retained and amended:

- Numerator to be amended to only include generic statin preparations listed under Category M in part VIII of the drug tariff.
- See appendices 1 and 2 for further details.

2. Omega-3 fatty acid compounds (new comparator)

A new comparator is to be introduced to support a new key therapeutic topic. See appendices 1 and 3 for further details.

3. Antidepressant ADQ/STAR-PU

The current comparator is to be retained and amended:

- Numerator amended to only measure total ADQs for the drugs included in the denominator used for the 'first choice' antidepressant comparator introduced in August 2012. Antidepressant (BNF 4.3)
- STAR-PU values to be reviewed for the amended numerator (above) and, if significantly different, denominator amended to utilise revised anti-depressant (subset) STAR-PU values.
- Comparator description to be amended to reflect the amended numerator and amended selected anti-depressant (sub-set) STAR-PU values (if amended).
- See appendices 1 and 4 for further details.

4. Long/intermediate acting insulin analogues

The current comparator is to be retained and amended:

- Numerator to be amended to include degludec (a new long acting insulin analogue available from February 2013).
- Comparator title to be amended from 'Long/intermediate acting insulin analogues' to 'Long-acting insulin analogues'
- Comparator description to be amended to remove specific reference to detemir and glargine and therefore including all current and any future long-acting insulin analogues.
- See appendices 1 and 5 for further details.

Appendix 1: Amendments and additions to QIPP prescribing comparators

Comparator	Comparator description (current)	Changes from Q1 2013/14 data (available August 2013)	
Laxatives ADQ/STAR PU	Total number of average daily quantities (ADQs) for laxatives per STAR-PU	Retain. No changes to current comparator.	
ACE inhibitor % items	Number of prescription items for angiotensin converting enzyme (ACE) inhibitors as a percentage of the total number of prescription items for all drugs affecting the renin-angiotensin system excluding aliskiren.	Retain. No changes to current comparator.	
Low cost lipid modifying drugs	Number of prescription items for simvastatin and pravastatin as a percentage of the total number of prescription items for all statins, plus the total number of prescription items for combination of simvastatin/ezetimibe, plus total number of prescription items for ezetimibe alone.	Retain and amend from Q1 2013/14 data. Numerator to be amended to only include generic statin preparations listed under Category M in part VIII of the drug tariff. See appendix 2 for further details.	
Lipid modifying drugs: Ezetimibe % items	Number of items for ezetimibe and ezetimibe/simvastatin combinations as a percentage of the total number of prescription items for all statins, plus the total number of prescription items for combination of simvastatin/ezetimibe, plus total number of prescription items for ezetimibe alone.	Retain. No changes to current comparator.	
Omega-3 fatty acid compounds	N/A (new comparator)	New comparator to be introduced from Q1 2013/14 data. Total number of ADQs for omega-3 fatty acid compounds per STAR-PU See appendix 3 for further details	
Hypnotics ADQ/STAR PU	Total number of average daily quantities (ADQs) for benzodiazepines (indicated for use as hypnotics) and 'Z' drugs per STAR-PU	Retain. No changes to current comparator.	

Comparator	Comparator description (current)	Changes from Q1 2013/14 data (available August 2013)
Antidepressants: ADQ/STAR PU	Total number of average daily quantities (ADQs) for all antidepressant prescribing (BNF 4.3) per STAR-PU	Retain and amend from Q1 2013/14 data. Amend numerator from 'all antidepressants (BNF 4.3)' to that of the denominator of the 'first choice % items' comparator (below). i.e. only measure total number of ADQs for 'selected' antidepressants. Amend denominator to utilise a revised anti-depressant (subset) STAR-PU values (NB: only if significantly different to antidepressant (BNF 4.3) STAR-PU values). Amend comparator description to reflect the amended numerator and amended denominator (if amended). See appendix 4 for further details.
Antidepressants: First choice % items	Number of prescription items for '1st choice' generic SSRIs as a percentage of the total number of prescription items for selected 'other antidepressants'	Retain. No changes to current comparator.
Antibacterial items/STAR PU	Number of prescription items for antibacterial drugs (BNF 5.1) per STAR-PU	Retain. No changes to current comparator.
Cephalosporins & quinolones % items	Number of prescription items for cephalosporins and quinolones as a percentage of the total number of prescription items for selected antibacterial drugs (BNF 5.1)	Retain No changes to current comparator.
3 days trimethoprim ADQ/item	Total number of average daily quantities (ADQs) per item for trimethoprim 200mg tablets.	Retain. No changes to current comparator.
Minocycline ADQ/1000 patients	Total number of average daily quantities (ADQs) for minocycline per 1000 patients	Retain. No changes to current comparator.

Comparator	Comparator description (current)	Changes from Q1 2013/14 data (available August 2013)
Hypoglycaemic drugs	Number of prescription items for metformin and	Retain.
	sulfonylureas as a percentage of the total number of prescription items for all antidiabetic drugs.	No changes to current comparator.
		NB: Proposed that comparator name will be changed to 'Antidiabetic drugs' (as per BNF section 6.1.2) following the next revision to "Key therapeutic topics" publication.
Long/intermediate insulin	Number of prescription items for long acting human	Retain and amend from Q1 2013/14 data.
analogues	analogue insulins detemir and glargine as a percentage of the total number of prescription items for all long acting and intermediate acting insulins	Amend numerator to include degludec (new long acting insulin analogue).
	excluding biphasic insulins.	Amend comparator title to 'Long-acting insulin analogues'
		Amend comparator description to remove specific reference to detemir and glargine and therefore include all available long-acting analogue insulins (current and future).
		See appendix 5 for further details
NSAIDs: Ibuprofen & naproxen % items	Number of prescription items for ibuprofen and naproxen as a percentage of the total number of prescription items for all NSAIDs.	Retain. No changes to current comparator.
NSAIDs: ADQ/STAR PU	Total number of average daily quantities (ADQs) for all NSAIDs (BNF 10.1.1) per STAR-PU	Retain. No changes to current comparator.
Wound care products: NIC/item	Cost (NIC) per item for wound care products	Retain. No changes to current comparator.
		Comparator to be reviewed post NHS reforms with consideration to the options implemented locally for community nurse prescribing cost centres.

Appendix 2: Details of changes to 'Low cost lipid modifying drugs' comparator

			Changes from Q1 2013/14 data	
Comparator title	Low cost lipid modifying drugs		Title to remain unchanged	
Comparator	•	tems for simvastatin and	Number of prescription items for go	
description	pravastatin as a percentage of the total number of prescription items for all statins, plus the total number of prescription items for combination of simvastatin/ezetimibe, plus total number of prescription items for ezetimibe alone.		total number of prescription items to of prescription items for combination total number of prescription items to	for ezetimibe alone.
Numerator	Number of prescription i pravastatin (sub-set of E	tems for simvastatin and BNF 2.12)	Number of prescription items for generic statin preparations listed under category M in part VIII of the Drug Tariff (sub-set of BNF 2.12) ¹	
	BNF Name	BNF Code	BNF Name	BNF Code
	Pravastatin Sodium	0212000X0	Atorvastatin_Tab 10mg	0212000B0AAAAA
	Simvastatin 0212000Y0	0212000Y0	Atorvastatin_Tab 20mg	0212000B0AAABAB
			Atorvastatin_Tab 40mg	0212000B0AAACAC
			Atorvastatin_Tab 80mg	0212000B0AAADAD
			Fluvastatin Sod_Cap 20mg	0212000M0AAAAA
			Fluvastatin Sod_Cap 40mg	0212000M0AAABAB
		Pravastatin Sod_Tab 10mg	0212000X0AAAAA	
			Pravastatin Sod_Tab 20mg	0212000X0AAABAB
			Pravastatin Sod_Tab 40mg	0212000X0AAADAD
		Simvastatin_Tab 10mg	0212000Y0AAAAAA	
		Simvastatin_Tab 20mg	0212000Y0AAABAB	
		Simvastatin_Tab 40mg	0212000Y0AAADAD	
			Simvastatin_Tab 80mg	0212000Y0AAAHAH

Denominator	Number of prescription items for all statins, including combination of simvastatin / ezetimibe, and ezetimibe (sub-set of BNF 2.12).		Denominator to remain unchanged (see left)
	BNF Name	BNF Code	
	Atorvastatin	0212000B0	
	Cerivastatin	0212000C0	
	Ezetimibe	0212000L0	
	Fluvastatin Sodium	0212000M0	
	Lovastatin	0212000R0	
	Pravastatin Sodium	0212000X0	
	Rosuvastatin Calcium	0212000AA	
	Simvastatin	0212000Y0	
	Simvastatin & Ezetimibe	0212000AC	

¹ Numerator will be reviewed prior to release of quarterly data to reflect current category M preparations listed in part VIII latest edition of the Drug Tariff

Appendix 3: Specification for new comparator "Omega-3 fatty acid compounds"

STAR-PU		
Omega-3 ADQ/STAR PU		
Total number of average daily quantities for Omega-3 fatty acid compounds		
BNF Name BNF Code		
Omega-3 Marine Triglycerides 0212000V0		
Omega-3-Acid Ethyl Esters 0212000AB		
Average Daily Quantity values are available for both chemical substances		
Omega-3 Marine Triglycerides ADQ = 10g		
Omega-3-Acid Ethyl Esters ADQ = 1g		
Number of ADQ based 'Omega-3 fatty acid compounds' STAR-PUs		
STAR-PU values currently being developed. Values will be provided when available.		

Appendix 4: Details of changes to 'Antidepressant ADQ/STAR-PU' comparator

	Current comparator		Proposed changes	
Comparator title	Antidepressants: ADQ/STAR PU		Title to remain unchanged	
Comparator description	Total number of average daily Star-PU for all antidepressant		Total number of average daily qua- for selected antidepressant presc	
<u> </u>				
Numerator	Total average daily quantity (ADQ) usage for antidepressants (BNF 4.3)		Total ADQs for selected antidepre section 4.3)	essants (sub-set of BNF
	BNF Name	BNF Code	BNF Name	BNF Code
	Antidepressant Drugs	0403	Antidepressant Drugs	0403
			excluding:	
			BNF Name	BNF Code
			Amitriptyline Hydrochloride	0403010B0
			Clomipramine Hydrochloride	0403010F0
			Imipramine Hydrochloride	0403010N0
			Nortriptyline	0403010V0
			Trimipramine	0403010Y0
			Monoamine-Oxidase Inhibitors (MAOIs)	040302
			Flupentixol Hydrochloride	0403040F0
			NB: This numerator is the same a current antidepressants: % first ch	

Denominator

Number of cost-based antidepressant (BNF 4.3) STAR-PUs

BNF Name
Antidepressant Drugs

BNF Code

0403

Number of cost-based 'selected antidepressant (sub-set of BNF 4.3) STAR-PUs

NB: STAR-PU values currently being developed. Values will be provided when available.

Cost-based antidepressant STAR-PU				
Age Range	Male Weighting	Female Weighting		
0 to 4	0.000	0.000		
5 to 14	0.000	0.000		
15 to 24	0.600	1.300		
25 to 34	2.200	4.400		
35 to 44	4.100	8.000		
45 to 54	4.700	9.800		
55 to 64	5.400	9.100		
65 to 74	4.500	8.000		
75+	5.400	10.200		

Appendix 5: Details of changes to 'Long/intermediate acting insulin analogues' comparator

	Current comparator		Proposed changes	
Comparator title	Long/intermediate insulin analogues		Change title to 'Long-acting insulin analogues'	
Comparator description	Number of prescription items for long acting human analogue insulins detemir and glargine as a percentage of the total number of prescription items for all long acting and intermediate acting insulins excluding biphasic insulins.		Number of prescription items for long-acting human analogue insulins as a percentage of the total number of prescription items for all long acting and intermediate acting insulins excluding biphasic insulins.	
Numerator	Number of prescription items for insul insulin glargine (sub-set of BNF section		Number of prescription item (sub-set of BNF section 6.1.	s for long-acting insulin analogues 1.2)
	BNF Name BN	F Code	BNF Name	BNF Code
	Insulin Detemir 060	1012X0	Insulin Degludec	0601012Z0
	Insulin Glargine 0601012V0		Insulin Detemir	0601012X0
			Insulin Glargine	0601012V0
Denominator	Number of prescription items for all long acting and intermediate acting insulins excluding* biphasic insulins (sub-set of BNF section 6.1.1.2). Denominator to remain unchanged (see left of:		nanged (see left) with the addition	
	BNF Name	BNF Code	BNF Name	BNF Code
	Insulin Detemir	0601012X0	Insulin Degludec	0601012Z0
	Insulin Glargine	0601012V0		
	Insulin Zinc Suspension 0601012G0			
	Insulin Zinc Suspension (Amorphous) 0601012L0			
	Insulin Zinc Suspension (Crystalline) 0601012N0			
	Isophane Insulin 0601012S0			
	Other Intermed&Long-Acting Insulin Preps 060101200			
	Protamine Zinc Insulin	0601012U0		